U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H26N5O8.Gd
Molecular Weight 573.6591
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GADODIAMIDE

SMILES

CN=C(CN(CCN(CCN(CC(=NC)[O-])CC(=O)O)CC(=O)[O-])CC(=O)O)[O-].[Gd+3]

InChI

InChIKey=HZHFFEYYPYZMNU-UHFFFAOYSA-K
InChI=1S/C16H29N5O8.Gd/c1-17-12(22)7-20(10-15(26)27)5-3-19(9-14(24)25)4-6-21(11-16(28)29)8-13(23)18-2;/h3-11H2,1-2H3,(H,17,22)(H,18,23)(H,24,25)(H,26,27)(H,28,29);/q;+3/p-3

HIDE SMILES / InChI
Gadodiamide is a nonionic, low-osmolar gadolinium-based contrast agent for diagnostic contrast-enhanced magnetic resonance imaging (MRI).

CNS Activity

Curator's Comment:: A 2015 study found trace amounts of Gadolinium deposited in the brain tissue of patients that had received Gadodiamide.

Originator

Curator's Comment:: Gadodiamide was developed by Salutar (Sunnyvale, Calif).

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
OMNISCAN

Approved Use

Diagnostic magnetic resonance imaging (MRI) indicated for intravenous use to visualize lesions with abnormal vascularity in the brain, spine, and associated tissues; facilitate the visualization of lesions with abnormal vascularity within the thoracic, abdominal, pelvic cavities, and the retroperitoneal space.

Launch Date

7.4416318E11
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
77.8 min
0.1 mmol/kg single, intravenous
dose: 0.1 mmol/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GADODIAMIDE unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
100%
0.1 mmol/kg single, intravenous
dose: 0.1 mmol/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GADODIAMIDE unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Neurotoxic potential of gadodiamide after injection into the lateral cerebral ventricle of rats.
1998 Sep
Gadolinium arteriography complicated by acute pancreatitis and acute renal failure.
2001 Mar
Gadodiamide-associated nephrogenic systemic fibrosis.
2007 Jun
Gadolinium-associated nephrogenic systemic fibrosis: double dose, not single dose.
2007 Jun
Case-control study of gadodiamide-related nephrogenic systemic fibrosis.
2007 Nov
Comparison of the usefulness of gadodiamide and iodine mixture versus iodinated contrast alone for prevention of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography.
2007 Oct 1
Nephrogenic systemic fibrosis: possible association with a predisposing infection.
2008 Apr
A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
2008 Jan
Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis.
2008 Mar
An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital.
2008 May
Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents.
2009 May
NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis.
2010 Nov
Intrathecal gadodiamide for identifying subarachnoid and ventricular neurocysticercosis.
2015 Jul
Investigation of the ototoxicity of gadoteridol (ProHance) and gadodiamide (Omniscan) in mice.
2016 Nov
Patents

Patents

Sample Use Guides

0.2 mL/kg (CNS), 0.1 mL/kg (kidney), 0.2 mL/kg (Intrathoracic, intra-abdominal, and pelvic cavities)
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Name Type Language
GADODIAMIDE
HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
GADODIAMIDE [USP-RS]
Common Name English
GADODIAMIDE [WHO-DD]
Common Name English
GADODIAMIDE ANHYDROUS
Common Name English
GADODIAMIDE [USP MONOGRAPH]
Common Name English
GDDTPA-BMA
Code English
S-041
Code English
OMNISCAN
Brand Name English
GADODIAMIDE [HSDB]
Common Name English
GADODIAMIDE [VANDF]
Common Name English
GADODIAMIDE [ORANGE BOOK]
Common Name English
(5,8-BIS(CARBOXYMETHYL)-11-(2-(METHYLAMINO)-2-OXOETHYL)-3-OXO-2,5,8,11-TETRAAZATRIDECAN-13-OATO(3-))GADOLINIUM
Common Name English
GADODIAMIDE [USAN]
Common Name English
GADODIAMIDE [INN]
Common Name English
GADODIAMIDE [MI]
Common Name English
GADODIAMIDE [MART.]
Common Name English
(N,N-BIS(2-((CARBOXYMETHYL)((METHYLCARBAMOYL)METHYL)AMINO)ETHYL)GLYCINATO(3-))GADOLINIUM
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 268408
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
NCI_THESAURUS C62358
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
WHO-VATC QV08CA03
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
NDF-RT N0000180184
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
NDF-RT N0000175862
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
WHO-ATC V08CA03
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
EU-Orphan Drug EU/3/08/583
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C65795
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
PRIMARY
USP_CATALOG
1287507
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
PRIMARY USP-RS
EVMPD
SUB126939
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
PRIMARY
WIKIPEDIA
GADODIAMIDE
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
PRIMARY
MESH
C064925
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
PRIMARY
FDA UNII
84F6U3J2R6
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
PRIMARY
RXCUI
41144
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
PRIMARY RxNorm
CAS
131410-48-5
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
PRIMARY
DRUG CENTRAL
4494
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
PRIMARY
MERCK INDEX
M5624
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
PRIMARY Merck Index
PUBCHEM
153921
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
PRIMARY
LACTMED
Gadodiamide
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
PRIMARY
ChEMBL
CHEMBL1200346
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
PRIMARY
HSDB
7547
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
PRIMARY
EVMPD
SUB07862MIG
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
PRIMARY
INN
6636
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
PRIMARY
DRUG BANK
DB00225
Created by admin on Fri Jun 25 20:54:33 UTC 2021 , Edited by admin on Fri Jun 25 20:54:33 UTC 2021
PRIMARY